SOL-GEL TECHN. IS-10 Asset Resilience Ratio
SOL-GEL TECHN. IS-10 asset resilience ratio. SOL-GEL TECHN. IS-10 (4SG) has an Asset Resilience Ratio of 58.16% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SOL-GEL TECHN. IS-10 liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SOL-GEL TECHN. IS-10 (2021–2025)
Asset resilience ratio of SOL-GEL TECHN. IS-10 from 2021 to 2025. This chart shows how SOL-GEL TECHN. IS-10's Asset Resilience Ratio has changed over time. Read 4SG total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SOL-GEL TECHN. IS-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SOL-GEL TECHN. IS-10 (4SG) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €31.27 Million | 58.16% |
| Total Liquid Assets | €31.27 Million | 58.16% |
Asset Resilience Insights
- Very High Liquidity: SOL-GEL TECHN. IS-10 maintains exceptional liquid asset reserves at 58.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SOL-GEL TECHN. IS-10 Industry Peers by Asset Resilience Ratio
Compare SOL-GEL TECHN. IS-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
SOL-GEL TECHN. IS-10 Asset Resilience Ratio by Year (2021–2025)
SOL-GEL TECHN. IS-10 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for SOL-GEL TECHN. IS-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.34% | €12.97 Million ≈ $15.16 Million |
€29.92 Million ≈ $34.98 Million |
+30.96pp |
| 2024-12-31 | 12.38% | €4.44 Million ≈ $5.19 Million |
€35.85 Million ≈ $41.91 Million |
-54.93pp |
| 2023-12-31 | 67.31% | €30.48 Million ≈ $35.64 Million |
€45.29 Million ≈ $52.95 Million |
+21.89pp |
| 2022-12-31 | 45.42% | €21.18 Million ≈ $24.76 Million |
€46.63 Million ≈ $54.51 Million |
+11.95pp |
| 2021-12-31 | 33.47% | €23.16 Million ≈ $27.07 Million |
€69.19 Million ≈ $80.89 Million |
-- |
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more